FOP Friends and FOP France renewed partnership with SGC Oxford

FOP friends FOP France

SGC at the University of Oxford is pleased to announce that two patient foundations, FOP Friends and FOP France, have renewed their long standing partnership with SGC Oxford to support research into the rare congenital syndrome fibrodysplasia ossificans progressiva (FOP). The research led by Dr Alex Bullock aims to better define the molecular mechanisms that cause FOP and to develop new treatments. In 2019, the team are hoping to initiate a phase II clinical trial to evaluate the investigational drug saracatinib (AZD0530) as a therapeutic agent for FOP though inhibition of the mutated ACVR1/ALK2 receptor protein which is aberrantly activated in FOP. SGC is grateful to the many FOP patients, families and friends who have helped to make this support possible.

glqxz9283 sfy39587stf02 mnesdcuix8